eFFECTOR Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update Portfolio News / Karina Tin November 8, 2021 eFFECTOR Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update Read More »
ORIC Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Update Portfolio News / Karina Tin November 8, 2021 ORIC Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Update Read More »
Neurona Therapeutics Presents Preclinical Data from Lead Cell Therapy Candidate NRTX-1001 at Neuroscience 2021 Portfolio News / Karina Tin November 8, 2021 Neurona Therapeutics Presents Preclinical Data from Lead Cell Therapy Candidate NRTX-1001 at Neuroscience 2021 Read More »
NGM Bio Provides Business Highlights and Reports Third Quarter 2021 Financial Results Portfolio News / Karina Tin November 4, 2021 NGM Bio Provides Business Highlights and Reports Third Quarter 2021 Financial Results Read More »
ORIC Pharmaceuticals to Present Update on CD73 Inhibitor Program in Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting Portfolio News / Karina Tin November 4, 2021 ORIC Pharmaceuticals to Present Update on CD73 Inhibitor Program in Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting Read More »
Neurona Therapeutics Receives IND Clearance to Initiate Phase 1/2 Clinical Trial of Neural Cell Therapy NRTX-1001 in Chronic Focal Epilepsy Patients Portfolio News / Karina Tin November 4, 2021 Neurona Therapeutics Receives IND Clearance to Initiate Phase 1/2 Clinical Trial of Neural Cell Therapy NRTX-1001 in Chronic Focal Epilepsy Patients Read More »
Plexium Appoints Percival Barretto-Ko as President and Chief Executive Officer Portfolio News / Karina Tin November 4, 2021 Plexium Appoints Percival Barretto-Ko as President and Chief Executive Officer Read More »
Synthekine Establishes Collaboration with Merck to Develop Therapeutic Candidates Using its Proprietary Surrogate Cytokine Agonist Platform Portfolio News / Karina Tin November 1, 2021 Synthekine Establishes Collaboration with Merck to Develop Therapeutic Candidates Using its Proprietary Surrogate Cytokine Agonist Platform Read More »
Synthekine Advances IL-2 Partial Agonist, STK-012, into Clinical Investigation for Treatment of Solid Tumors Portfolio News / Karina Tin October 28, 2021 Synthekine Advances IL-2 Partial Agonist, STK-012, into Clinical Investigation for Treatment of Solid Tumors Read More »
Nurix Therapeutics Announces Initial Data from the First Phase 1a Dose Escalation Trial of NX-2127 in Patients with Relapsed or Refractory B Cell Malignancies Portfolio News / Karina Tin October 27, 2021 Nurix Therapeutics Announces Initial Data from the First Phase 1a Dose Escalation Trial of NX-2127 in Patients with Relapsed or Refractory B Cell Malignancies Read More »